ASRC Press Releases

NAD Finds Chattem Can Support Challenged Claims for ‘Nasacort’ Following Merck Challenge

NAD has determined that sanofi-aventis, sanofi-aventis U.S. and Chattem, Inc., can support certain advertising claims for “Nasacort Allergy 24HR,” an over-the-counter allergy relief medication. The claims were challenged by MSD Consumer Care, Inc., a/k/a Merck Consumer Care.

Read More

ERSP Recommends Real Freedom, Inc. Modify, Discontinue Certain Claims for Real Estate Mogul; Company Agrees to Do So

ERSP has recommended that Real Freedom, Inc., modify or discontinue certain claims for the Real Estate Mogul real estate investing education program, including claims related to earnings.

Read More

CARU Recommends CDE Modify Website to Better Protect Children’s Privacy; Company Agrees to Do So

CARU has recommended that Cartoondollemporium.com modify its website to better protect children’s privacy. The company has agreed to do so.

Read More

ERSP Reviews Advertising for ‘Jidue,’ Recommends Marketer Modify or Discontinue Certain Claims

ERSP has recommended that Audy Global modify or discontinue claims for “Jidue,” a facial massager intended to help reduce eye puffiness, facial tension, and wrinkles.

Read More

CARU Recommends CEC Modify Advertising for Chuck E. Cheese Sweepstakes

CARU has recommended that that CEC modify sweepstakes advertising for “Chuck E. Cheese’s Rip It, Sip It, Win It Sweepstakes,” which appeared during children’s programming.

Read More

NAD Recommends Fiore Rx Discontinue Claims for Company’s ‘Antifungal’ Nail Polish

In response to an inquiry from the NAD, Fiore Rx, LLC – the maker of Fiore Rx “Antifungal Nail Lacquer” – said it has modified or discontinued certain claims that reference the antifungal effects of its product on nails, as well as claims that reference the FDA.

Read More